Tumor Therapy:- Announcing a new publication for Acta Materia Medica journal. Cancer is the leading cause of morbidity and mortality worldwide and is an important barrier to lengthening life expectancy in every country.[Pixabay] 
Health

Role of natural products in tumor therapy from basic research and clinical perspectives

Announcing a new publication for Acta Materia Medica journal. Cancer is the leading cause of morbidity and mortality worldwide and is an important barrier to lengthening life expectancy in every country.

Author : NewsGram Desk

Tumor Therapy:- Announcing a new publication for Acta Materia Medica journal. Cancer is the leading cause of morbidity and mortality worldwide and is an important barrier to lengthening life expectancy in every country. Natural products are receiving increased attention from researchers globally and increasing numbers of natural products are approved for clinical studies involving cancer in recent years.

A comprehensive search was conducted to gain more insight into natural products that have undergone clinical trials for cancer treatment.
This article lists existing clinical trials about natural products used in the treatment of cancers and discusses the preclinical and clinical studies of some promising natural products and their targets, indications, and underlying mechanisms of action.

The intent is to provide basic information to readers who are interested or majoring in natural products and obtain a deeper understanding of the progress and actions of natural product mechanisms of action. AlphaGalileo/SP

Subscribe to our channels on YouTube and WhatsApp 

12 Top Maoist Leaders Surrender Today in Chhattisgarh; Major Breakthrough in Anti-Naxal Drive

Parliament Winter Session 2025: Live Updates Day 6 - 'Vande Mataram' Discussion Continues in Lok Sabha

“150 Glorious Years of Vande Mataram”- Debate in Lok Sabha Today; Why Jawaharlal Nehru Chose 'Jana Gana Mana' as The National Anthem over 'Vande Mataram'

AI-Based Diagnostic Tools Boosting TB, Diabetes Care: Govt

Biocon to Fully Integrate Biologics Unit in $5.5 Billion Deal